Iron Financial LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 5.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,319 shares of the company’s stock after acquiring an additional 278 shares during the period. Johnson & Johnson comprises approximately 0.4% of Iron Financial LLC’s holdings, making the stock its 28th largest position. Iron Financial LLC’s holdings in Johnson & Johnson were worth $792,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Morgan Stanley grew its position in Johnson & Johnson by 0.3% in the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after purchasing an additional 54,563 shares during the period. Kessler Investment Group LLC grew its position in Johnson & Johnson by 6,926.0% in the 2nd quarter. Kessler Investment Group LLC now owns 14,052 shares of the company’s stock worth $1,976,000 after purchasing an additional 13,852 shares during the period. Private Wealth Advisors Inc. grew its position in Johnson & Johnson by 1.3% in the 2nd quarter. Private Wealth Advisors Inc. now owns 21,217 shares of the company’s stock worth $2,984,000 after purchasing an additional 266 shares during the period. Oregon Public Employees Retirement Fund grew its position in Johnson & Johnson by 51.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 880,478 shares of the company’s stock worth $123,822,000 after purchasing an additional 298,622 shares during the period. Finally, Highland Private Wealth Management grew its position in Johnson & Johnson by 6.0% in the 2nd quarter. Highland Private Wealth Management now owns 10,387 shares of the company’s stock worth $1,461,000 after purchasing an additional 585 shares during the period. Institutional investors own 67.44% of the company’s stock.
A number of research firms have commented on JNJ. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Finally, Cantor Fitzgerald boosted their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $164.93.
JNJ opened at $146.36 on Friday. The firm’s fifty day moving average is $145.51 and its 200 day moving average is $146.57. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The stock has a market cap of $385.30 billion, a price-to-earnings ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business’s revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.12 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.27% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.